A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Sign up to get exclusive coupon discounts and be the first to be notified when we have this product available.
Lotensin HCT contains a combination of two different prescription drugs for the treatment of high blood pressure. If left untreated, high blood pressure can increase the risk of heart attack and stroke, which are debilitating and sometimes fatal.
Lotensin is available in a variety of different strengths, including
Take Lotensin HCT exactly as directed by your healthcare provider. It is usually taken once or twice daily.
The active ingredients in Lotensin HCT are benazepril and hydrochlorothiazide.
Benazepril is an angiotensin-converting enzyme (ACE) inhibitor. It works by preventing the formation of angiotensin II, which helps to regulate and decrease blood pressure.
Common drug-drug interactions may include:
Tell your doctor if you have a history of kidney or liver problems before starting this drug.
Stop taking Lotensin HCT if you suddenly develop an unexplained dry cough.
Your doctor should monitor your blood electrolytes when starting this drug and also periodically.
The most common side effects of this drug are:
Lotensin HCT [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2009.